Biodesix Reveals Two Developing MRD Solution Collaborations With Bio-Rad And Thermo Fisher

September 27, 2026 — 08:23 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Biodesix Inc. (BDSX), a diagnostic solutions company, last week reported strategic progress for two programmes regarding Molecular Residual Disease (MRD) solutions for cancer diagnosis. Biodesix is developing the tests for tumor-informed and tumor-naive MRD using its Diagnostics Cortex bioinformatics platform to identify genomics changes unique to an individual. These approaches detect circulating DNA (ctDNA) specific to the tumor-type being diagnosed. The tumor-informed method is being carried out in conjunction with Bio-Rad Laboratories Inc. (BIO). The test will utilize Bio-Rad's Droplet Digital PCR technology and is the result of a multi-year collaboration between the two companies. The tumor-naive test builds on newly launched, joint research with Thermo Fisher Scientific (TMO). Both programs are hosted at the Memorial Sloan-Kettering Cancer Center (MSK).

BDSX closed Friday at $29.10, down 1.02%.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Biodesix Reveals Two Developing MRD Solution Collaborations With Bio-Rad And Thermo Fisher

Tags

Latest Articles